{"id": "batch_req_GrGtTCGkrC59qRYlhlIZYHVU", "custom_id": "1_sentiment_question_about_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "75a73872315bd30a952c51611840a87f", "body": {"id": "chatcmpl-9RR1UfjHdL50RljM40UmAvzPPlLt2", "object": "chat.completion", "created": 1716325760, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Abemaciclib is a medication used primarily in the treatment of certain types of breast cancer. It belongs to a class of drugs known as CDK4/6 inhibitors, which work by interfering with the function of cyclin-dependent kinases 4 and 6. These kinases are enzymes that play a crucial role in cell division and proliferation. By inhibiting their activity, abemaciclib can help slow down or stop the growth of cancer cells.\n\nHere are some key points about abemaciclib:\n\n1. **Indications**: Abemaciclib is often prescribed for hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer. It is typically used in combination with hormone therapy (like an aromatase inhibitor or fulvestrant) or as a monotherapy in certain cases.\n\n2. **Administration**: The drug is taken orally, usually in the form of tablets. The dosage and treatment schedule depend"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 36, "completion_tokens": 200, "total_tokens": 236}, "system_fingerprint": "fp_c45f7d0b45"}}, "error": null}
{"id": "batch_req_atu0YWaUW328ZrLhgW6zbqOA", "custom_id": "2_sentiment_question_about_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "e6548be168935a41b9f2ce0cb30994dc", "body": {"id": "chatcmpl-9RR1UHvpSQEGYronj2Esp4kizfQAe", "object": "chat.completion", "created": 1716325760, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Abiraterone is a medication used primarily in the treatment of prostate cancer. It works by inhibiting the enzyme CYP17A1, which is involved in the production of androgens (male hormones) such as testosterone. Since prostate cancer cells often rely on androgens to grow and proliferate, reducing androgen levels can help slow the progression of the disease.\n\nHere are some key points about Abiraterone:\n\n1. **Indications**: Abiraterone is typically prescribed for metastatic castration-resistant prostate cancer (mCRPC) and sometimes for metastatic high-risk castration-sensitive prostate cancer (mCSPC).\n\n2. **Mechanism of Action**: By inhibiting CYP17A1, Abiraterone decreases the production of androgens not only in the testes but also in the adrenal glands and the tumor itself. This leads to lower levels of testosterone and other androgens in the body.\n\n3. **Administration**: Abiraterone is usually"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 36, "completion_tokens": 200, "total_tokens": 236}, "system_fingerprint": "fp_729ea513f7"}}, "error": null}
{"id": "batch_req_MPa5HdGNeHnwqQIsjGHDHnI1", "custom_id": "3_sentiment_question_about_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "4e686b53a31dec9f5d0c91ebd521dea2", "body": {"id": "chatcmpl-9RR1UOwLhEjootV8XvI6iTsprvmj5", "object": "chat.completion", "created": 1716325760, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Acalabrutinib, marketed under the brand name Calquence, is a medication used to treat certain types of blood cancers. It is specifically approved for the treatment of mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). Acalabrutinib is a type of targeted therapy known as a Bruton's tyrosine kinase (BTK) inhibitor.\n\n### Mechanism of Action\nAcalabrutinib works by inhibiting the activity of BTK, a protein that plays a crucial role in the survival and proliferation of B cells. By blocking BTK, acalabrutinib helps to prevent the growth and spread of cancerous B cells.\n\n### Administration\nAcalabrutinib is typically taken orally in the form of capsules. The dosage and treatment schedule can vary depending on the specific condition being treated and the patient's overall health.\n\n### Side Effects\nCommon side effects of acalabrutinib may include:\n"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 37, "completion_tokens": 200, "total_tokens": 237}, "system_fingerprint": "fp_729ea513f7"}}, "error": null}
{"id": "batch_req_hGWaz1e6DhTIWeOW51UtV3jw", "custom_id": "4_sentiment_question_about_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "ebd1296c3b9f9b45deccf422743cfdb2", "body": {"id": "chatcmpl-9RR1UadtoyyAx92B2UCRWGPh6uasY", "object": "chat.completion", "created": 1716325760, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Aclarubicin, also known as aclacinomycin A, is an anthracycline antibiotic that is primarily used in the treatment of certain types of cancer. It is derived from the bacterium *Streptomyces galilaeus*. Aclarubicin works by intercalating into DNA, thereby inhibiting the synthesis of nucleic acids and inducing apoptosis (programmed cell death) in cancer cells.\n\nHere are some key points about Aclarubicin:\n\n1. **Mechanism of Action**: Aclarubicin intercalates into DNA, disrupting the function of topoisomerase II, an enzyme crucial for DNA replication and repair. This leads to breaks in the DNA strands, ultimately causing cell death.\n\n2. **Uses**: It is used in the treatment of various types of leukemia, including acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). It may also be used in combination with other chemotherapeutic agents.\n\n3."}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 36, "completion_tokens": 200, "total_tokens": 236}, "system_fingerprint": "fp_927397958d"}}, "error": null}
{"id": "batch_req_knRmwcIYOYYiEVJcefEH3Z7s", "custom_id": "5_sentiment_question_about_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "71c03b21b5d7c4df68cbcda08b44a855", "body": {"id": "chatcmpl-9RR1VT6XBdu4vqrReLjcnV36Udh02", "object": "chat.completion", "created": 1716325761, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Trastuzumab emtansine, also known by its brand name Kadcyla, is a targeted cancer therapy used primarily in the treatment of HER2-positive breast cancer. It is an antibody-drug conjugate, which means it combines two components: trastuzumab and a chemotherapy drug called emtansine (DM1).\n\n1. **Trastuzumab**: This is a monoclonal antibody that specifically targets the HER2 receptor, a protein that can promote the growth of cancer cells. HER2 is overexpressed in some breast cancers, making them more aggressive. By binding to the HER2 receptor, trastuzumab helps to inhibit the growth of these cancer cells and can also mark them for destruction by the immune system.\n\n2. **Emtansine (DM1)**: This is a cytotoxic agent, meaning it is toxic to cells. It works by disrupting the microtubules within the cancer cells, which are essential for cell division and growth."}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_927397958d"}}, "error": null}
{"id": "batch_req_XnalHHnwTcTsSiDiRmZmzNBH", "custom_id": "6_sentiment_question_about_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "8b107e264122900123e8fa012cb45f6b", "body": {"id": "chatcmpl-9RR1VHWFSsm2k0Cv1MSKs37t1Mjbl", "object": "chat.completion", "created": 1716325761, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Afatinib is a medication used primarily in the treatment of non-small cell lung cancer (NSCLC). It is classified as a tyrosine kinase inhibitor (TKI) and works by blocking certain proteins called epidermal growth factor receptors (EGFR) that are involved in the growth and spread of cancer cells.\n\nHere are some key points about Afatinib:\n\n1. **Mechanism of Action**: Afatinib irreversibly binds to and inhibits the activity of EGFR and other members of the ErbB family of receptors, which are often overexpressed or mutated in various cancers. By inhibiting these receptors, Afatinib can help to slow down or stop the growth of cancer cells.\n\n2. **Indications**: Afatinib is primarily used to treat patients with metastatic NSCLC who have specific mutations in the EGFR gene. It is often prescribed when the cancer has progressed despite other treatments.\n\n3. **Administration**: Afatinib is taken orally, usually"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 35, "completion_tokens": 200, "total_tokens": 235}, "system_fingerprint": "fp_729ea513f7"}}, "error": null}
{"id": "batch_req_K4oZWNCVqRs5LzcKygCFnhwd", "custom_id": "7_sentiment_question_about_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "fe2bbf2dde4a9cb380ea192f5baa7eed", "body": {"id": "chatcmpl-9RR1VoxpNCLPFN9qkSXFNRb0UXGxm", "object": "chat.completion", "created": 1716325761, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Aldesleukin, also known by its brand name Proleukin, is a synthetic version of a protein called interleukin-2 (IL-2), which is naturally produced by the body. IL-2 is a type of cytokine, a protein that plays a crucial role in regulating the immune system. Aldesleukin is used as an immunotherapy treatment, primarily for certain types of cancer, including metastatic renal cell carcinoma (kidney cancer) and metastatic melanoma (a type of skin cancer).\n\nHere are some key points about Aldesleukin:\n\n1. **Mechanism of Action**: Aldesleukin works by stimulating the growth and activity of T-cells and natural killer (NK) cells, which are types of white blood cells that can attack cancer cells. By boosting the immune system, it helps the body to fight cancer more effectively.\n\n2. **Administration**: Aldesleukin is usually administered via intravenous infusion in a hospital setting due to the potential"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 36, "completion_tokens": 200, "total_tokens": 236}, "system_fingerprint": "fp_c45f7d0b45"}}, "error": null}
{"id": "batch_req_4q258Ujs6Ls0KM1MSd1Dh0LX", "custom_id": "8_sentiment_question_about_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "8076dc36d28c537253f3e081e89b67a3", "body": {"id": "chatcmpl-9RR1WL6Jh1IbrOn8jGlpE2eKzuE2Z", "object": "chat.completion", "created": 1716325762, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Alectinib is a medication used primarily in the treatment of non-small cell lung cancer (NSCLC). It is specifically indicated for patients whose tumors are anaplastic lymphoma kinase (ALK)-positive, which is a genetic alteration that can drive cancer growth. Alectinib works as a targeted therapy by inhibiting the activity of the ALK protein, thereby slowing or stopping the growth of cancer cells.\n\nHere are some key points about Alectinib:\n\n1. **Mechanism of Action**: Alectinib is an ALK inhibitor. By blocking the activity of the ALK protein, it helps to prevent the proliferation of cancer cells that have this specific genetic mutation.\n\n2. **Indications**: It is used for the treatment of ALK-positive metastatic NSCLC. It is often prescribed when the cancer has spread to other parts of the body and is not amenable to surgical removal.\n\n3. **Administration**: Alectinib is taken orally, usually in the"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 36, "completion_tokens": 200, "total_tokens": 236}, "system_fingerprint": "fp_729ea513f7"}}, "error": null}
{"id": "batch_req_stOD2Zjx22bA268k2t0EoRaz", "custom_id": "9_sentiment_question_about_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "0b5084c273152fce0154e3c2724c8bf5", "body": {"id": "chatcmpl-9RR1VMQCuwG7m8WPxU0ommplBfNOI", "object": "chat.completion", "created": 1716325761, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Alemtuzumab is a monoclonal antibody used primarily in the treatment of certain types of cancer and autoimmune diseases. Here are some key points about Alemtuzumab:\n\n1. **Mechanism of Action**: Alemtuzumab targets a protein called CD52, which is found on the surface of certain immune cells, including T and B lymphocytes. By binding to CD52, Alemtuzumab helps to deplete these cells, which can be beneficial in conditions where the immune system is overactive or in certain cancers.\n\n2. **Uses**:\n   - **Multiple Sclerosis (MS)**: Alemtuzumab is used to treat relapsing forms of multiple sclerosis. It is typically considered when other treatments have not been effective.\n   - **Chronic Lymphocytic Leukemia (CLL)**: It is used in the treatment of B-cell chronic lymphocytic leukemia.\n   - **Other Conditions**: Alemtuzumab has also been used off-label"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 36, "completion_tokens": 200, "total_tokens": 236}, "system_fingerprint": "fp_729ea513f7"}}, "error": null}
{"id": "batch_req_ErgcJd7ehndviCmdvZqDQKML", "custom_id": "10_sentiment_question_about_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "497c16515633456465fc7b3744407753", "body": {"id": "chatcmpl-9RR1Va0uhYLtMg0nhUREEvV259H6h", "object": "chat.completion", "created": 1716325761, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "All-trans retinoic acid (ATRA) is a derivative of vitamin A (retinol) and is a member of the retinoid family of compounds. It plays a crucial role in cell growth, differentiation, and apoptosis (programmed cell death). Here are some key points about ATRA:\n\n1. **Medical Uses**:\n   - **Acute Promyelocytic Leukemia (APL)**: ATRA is most notably used in the treatment of APL, a subtype of acute myeloid leukemia. It induces the differentiation of the immature cancerous cells into mature blood cells, which can then undergo normal cell death.\n   - **Dermatology**: ATRA is also used topically to treat various skin conditions, including acne, photoaging (skin damage caused by sunlight), and certain types of hyperpigmentation. It helps to normalize the shedding of dead skin cells and promotes the turnover of new skin cells.\n\n2. **Mechanism of Action**:\n   - A"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 38, "completion_tokens": 200, "total_tokens": 238}, "system_fingerprint": "fp_927397958d"}}, "error": null}
{"id": "batch_req_Kak2WkHyKwhPqqjsF1bQagG7", "custom_id": "1_sentiment_question_about_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "bf61364d96a5f61c69ee5c75eea67bcc", "body": {"id": "chatcmpl-9RR1VnIjiT5iPdJkbNUIfExVbfERx", "object": "chat.completion", "created": 1716325761, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Abemaciclib is a medication that is primarily used in the treatment of certain types of breast cancer. It belongs to a class of drugs known as cyclin-dependent kinase (CDK) inhibitors. Specifically, it inhibits CDK4 and CDK6, proteins that play a crucial role in cell division and proliferation. By inhibiting these proteins, Abemaciclib can help slow the growth and spread of cancer cells.\n\nHere are some key points about Abemaciclib:\n\n1. **Indications**: Abemaciclib is often used in combination with hormone therapy (like an aromatase inhibitor or fulvestrant) for the treatment of HR-positive, HER2-negative advanced or metastatic breast cancer. It can also be used as monotherapy for certain patients who have previously received endocrine therapy and chemotherapy.\n\n2. **Mechanism of Action**: By inhibiting CDK4 and CDK6, Abemaciclib prevents the phosphorylation of the retinoblastoma (Rb)"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 36, "completion_tokens": 200, "total_tokens": 236}, "system_fingerprint": "fp_927397958d"}}, "error": null}
{"id": "batch_req_PoAOAliFWvlNjO03A7rcfJgD", "custom_id": "2_sentiment_question_about_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "a3d276cba0287bb9c92277063da1239e", "body": {"id": "chatcmpl-9RR1VrlaKKNLuwmt21K2Z54tdPO9h", "object": "chat.completion", "created": 1716325761, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Abiraterone, commonly known by its brand name Zytiga, is a medication used primarily in the treatment of prostate cancer. Specifically, it is used in cases of metastatic castration-resistant prostate cancer (mCRPC), which is a form of the disease that has spread to other parts of the body and is not responding to treatments that lower testosterone levels.\n\n### Mechanism of Action\nAbiraterone works by inhibiting an enzyme called CYP17A1. This enzyme is crucial in the production of androgens (male hormones) not just in the testes, but also in the adrenal glands and prostate tumor tissue. Since androgens can stimulate the growth of prostate cancer cells, reducing their production can help control the progression of the disease.\n\n### Administration\nAbiraterone is typically administered in combination with prednisone, a corticosteroid. This combination helps to manage some of the side effects and enhances the effectiveness of the treatment. The drug is taken orally, usually once a day.\n\n"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 36, "completion_tokens": 200, "total_tokens": 236}, "system_fingerprint": "fp_927397958d"}}, "error": null}
{"id": "batch_req_2vf1hGyhVLhwyuclH6cvhVUI", "custom_id": "3_sentiment_question_about_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "de2f0ac6f1ff68fa9dee9b59050a5b2a", "body": {"id": "chatcmpl-9RR1aUU7xBiifAeO9N2lPCI3ZBSBz", "object": "chat.completion", "created": 1716325766, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Acalabrutinib is a medication used primarily in the treatment of certain types of blood cancers. It is an inhibitor of Bruton's tyrosine kinase (BTK), which plays a crucial role in the proliferation and survival of B cells, a type of white blood cell. By inhibiting BTK, acalabrutinib helps to slow down or stop the growth of cancerous B cells.\n\nAcalabrutinib is commonly used to treat:\n\n1. **Chronic Lymphocytic Leukemia (CLL):** A type of leukemia that typically affects older adults and involves the overproduction of abnormal B cells.\n2. **Mantle Cell Lymphoma (MCL):** A rare and aggressive form of non-Hodgkin lymphoma that arises from B cells in the lymph nodes.\n\nAcalabrutinib is taken orally, usually in the form of capsules. The dosing regimen can vary based on the specific condition being treated and the patient's overall health. As with any"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 37, "completion_tokens": 200, "total_tokens": 237}, "system_fingerprint": "fp_729ea513f7"}}, "error": null}
{"id": "batch_req_JnMOl6QXdNFj1kJszKUgyhVl", "custom_id": "4_sentiment_question_about_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "efcb4fe62ea1d64d8fef835eba1cb9ef", "body": {"id": "chatcmpl-9RR1WsBdoJhoCLDGv33E050kKS99H", "object": "chat.completion", "created": 1716325762, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Aclarubicin is an anthracycline antibiotic that is used primarily in the treatment of certain types of cancer, particularly acute myeloid leukemia (AML). It works by intercalating into DNA strands and inhibiting the synthesis of nucleic acids, which is crucial for cancer cell proliferation and survival. Here are some key points about Aclarubicin:\n\n1. **Mechanism of Action**: Aclarubicin intercalates into DNA and inhibits topoisomerase II, an enzyme essential for DNA replication and repair. This ultimately leads to the disruption of DNA synthesis and triggers cell death, particularly in rapidly dividing cancer cells.\n\n2. **Usage**: It is most commonly used in the treatment of hematologic malignancies, such as acute myeloid leukemia (AML). It may be used in combination with other chemotherapeutic agents to enhance its efficacy.\n\n3. **Administration**: Aclarubicin is typically administered intravenously. The dosage and treatment regimen depend on the"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 36, "completion_tokens": 200, "total_tokens": 236}, "system_fingerprint": "fp_927397958d"}}, "error": null}
{"id": "batch_req_8OLYDivQw3upgWcKQvLZebfa", "custom_id": "5_sentiment_question_about_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "44dc928d65888eaf04c97658bec401be", "body": {"id": "chatcmpl-9RR1WRroIZW7PJcmBUpIEXWJhboB5", "object": "chat.completion", "created": 1716325762, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Trastuzumab emtansine, also known by the brand name Kadcyla, is a targeted cancer therapy used primarily to treat certain types of breast cancer. It is an antibody-drug conjugate (ADC) that combines two components:\n\n1. **Trastuzumab (Herceptin)**: This is a monoclonal antibody that targets the HER2 (human epidermal growth factor receptor 2) protein. HER2 is overexpressed in some breast cancers and promotes the growth of cancer cells. Trastuzumab binds to the HER2 receptors on the surface of these cancer cells, inhibiting their growth and survival.\n\n2. **Emtansine (DM1)**: This is a cytotoxic agent (a chemotherapy drug) that is linked to trastuzumab. Emtansine is derived from maytansine and works by disrupting microtubules, which are essential for cell division. By preventing the cancer cells from dividing, it can lead to"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_729ea513f7"}}, "error": null}
{"id": "batch_req_QNVk5yhwhKI4Skzt7YmZkotY", "custom_id": "6_sentiment_question_about_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "5886456be5b91269825bd06b3fde4a17", "body": {"id": "chatcmpl-9RR1WfwGBG2UiNwMWfulu681VbwrA", "object": "chat.completion", "created": 1716325762, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Afatinib is a medication used primarily for the treatment of certain types of non-small cell lung cancer (NSCLC). It belongs to a class of drugs known as tyrosine kinase inhibitors. Specifically, Afatinib irreversibly blocks a family of enzymes called epidermal growth factor receptor (EGFR) tyrosine kinases, which are involved in the growth and spread of cancer cells.\n\nHere are some key points about Afatinib:\n\n1. **Mechanism of Action**: Afatinib works by irreversibly binding to and inhibiting the EGFRs, which can be overactive in some cancer cells. By blocking these receptors, Afatinib helps to slow down or stop the growth of cancer cells.\n\n2. **Indications**: It is typically prescribed for patients with metastatic NSCLC who have specific mutations in the EGFR gene. These mutations are usually identified through genetic testing of the tumor tissue.\n\n3. **Administration**: Afatinib is taken orally,"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 35, "completion_tokens": 200, "total_tokens": 235}, "system_fingerprint": "fp_927397958d"}}, "error": null}
{"id": "batch_req_j9zZi6tX5OxoU0vSyFDJMuLO", "custom_id": "7_sentiment_question_about_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "e1c6f5a1a1ae4d0e2632ccbc18d8a40f", "body": {"id": "chatcmpl-9RR1WtkNiRWsdeYQc6EquLUnMEyYj", "object": "chat.completion", "created": 1716325762, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Aldesleukin, also known by its brand name Proleukin, is a recombinant form of interleukin-2 (IL-2), a protein that is naturally produced by the body\u2019s immune system. This medication is primarily used as an immunotherapy treatment for certain types of cancers, particularly metastatic renal cell carcinoma (kidney cancer) and metastatic melanoma (skin cancer).\n\n### Mechanism of Action:\nAldesleukin works by stimulating the growth and activity of white blood cells, particularly T-lymphocytes and natural killer (NK) cells. This enhancement of the immune response helps the body to attack and destroy cancer cells more effectively.\n\n### Administration:\nAldesleukin is administered via intravenous infusion, typically in a hospital or clinical setting. The dosing schedule can vary, but it often involves cycles of treatment followed by rest periods to allow the body to recover.\n\n### Side Effects:\nLike many cancer treatments, Aldesleukin can have significant side effects. Common side effects"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 36, "completion_tokens": 200, "total_tokens": 236}, "system_fingerprint": "fp_729ea513f7"}}, "error": null}
{"id": "batch_req_peTftYPu2qn2huQqKcJUYwu8", "custom_id": "8_sentiment_question_about_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "958147197a30693d91b0e14410eb141b", "body": {"id": "chatcmpl-9RR1WpHSfpl8MltjZr8YdoOUPvXHt", "object": "chat.completion", "created": 1716325762, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Alectinib is a medication used primarily for the treatment of non-small cell lung cancer (NSCLC) that is anaplastic lymphoma kinase (ALK)-positive. It is a targeted therapy, which means it works by specifically targeting cancer cells with a particular genetic mutation or characteristic\u2014in this case, the ALK gene rearrangement.\n\nHere are some key points about Alectinib:\n\n1. **Mechanism of Action**: Alectinib is a tyrosine kinase inhibitor that targets and inhibits the activity of the ALK protein. This inhibition helps to block the growth and spread of cancer cells that have this mutation.\n\n2. **Indications**: Alectinib is typically prescribed for patients with ALK-positive NSCLC, particularly those who have not responded to or cannot tolerate other treatments, such as crizotinib, another ALK inhibitor.\n\n3. **Administration**: It is usually taken orally in the form of capsules. The standard dosing schedule is twice daily.\n\n"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 36, "completion_tokens": 200, "total_tokens": 236}, "system_fingerprint": "fp_729ea513f7"}}, "error": null}
{"id": "batch_req_hLhuimWdzxybXyUclJ1gc0Rc", "custom_id": "9_sentiment_question_about_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "9e0b1c086c2ecdacc4c34968ea4f3c2f", "body": {"id": "chatcmpl-9RR1Wi7ldi8AghRjUH7Siqo28zFkH", "object": "chat.completion", "created": 1716325762, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Alemtuzumab is a monoclonal antibody used as a medication primarily to treat certain types of cancer and autoimmune conditions. Here are some key points about Alemtuzumab:\n\n1. **Mechanism of Action**: Alemtuzumab targets the CD52 protein, which is found on the surface of mature lymphocytes (a type of white blood cell). By binding to CD52, Alemtuzumab initiates the destruction of these cells, which can help in conditions where the immune system is overactive or in certain cancers where these cells proliferate abnormally.\n\n2. **Uses**:\n   - **Chronic Lymphocytic Leukemia (CLL)**: Alemtuzumab is approved for the treatment of B-cell chronic lymphocytic leukemia.\n   - **Multiple Sclerosis (MS)**: It is used to treat relapsing forms of multiple sclerosis. It can reduce the frequency of relapses and slow the progression of physical disability.\n   - **Other Conditions**"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 36, "completion_tokens": 200, "total_tokens": 236}, "system_fingerprint": "fp_729ea513f7"}}, "error": null}
{"id": "batch_req_Y1c8Jz4y9lBpeOtMCs0wAOvE", "custom_id": "10_sentiment_question_about_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "b6dbf61b2b23aff478ce8d475114ebb9", "body": {"id": "chatcmpl-9RR1WkbI31FgTeqKBx4A6FKXDfg4z", "object": "chat.completion", "created": 1716325762, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "All-trans retinoic acid (ATRA) is a derivative of vitamin A (retinol) and is an important compound in the field of medicine, particularly in the treatment of certain types of cancer and skin conditions. Here are some key points about all-trans retinoic acid:\n\n### Chemical Properties:\n- **Chemical Formula**: C20H28O2\n- **Structure**: ATRA is an acid form of vitamin A with a linear structure, differing from its isomers like 13-cis-retinoic acid (isotretinoin).\n\n### Medical Uses:\n1. **Acute Promyelocytic Leukemia (APL)**:\n   - ATRA is notably used in the treatment of APL, a subtype of acute myeloid leukemia. It induces the differentiation of promyelocytes (immature white blood cells) into mature cells, reducing the number of proliferating immature cells.\n   - When used in combination with other chemotherapeutic agents like arsenic tr"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 38, "completion_tokens": 200, "total_tokens": 238}, "system_fingerprint": "fp_729ea513f7"}}, "error": null}
{"id": "batch_req_gQY64QsWmQDItcKDkeoKtqBn", "custom_id": "1_sentiment_question_about_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "5ed18fce6e91168f1ecc2a93904e8490", "body": {"id": "chatcmpl-9RR1WjJvxYFHHQ1o1HsDr6IZlBByl", "object": "chat.completion", "created": 1716325762, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Abemaciclib, brand name Verzenio, is a medication used in the treatment of certain types of breast cancer. It belongs to a class of drugs known as CDK4/6 inhibitors, which work by blocking proteins called cyclin-dependent kinases 4 and 6. These proteins play a crucial role in cell division and growth, and by inhibiting them, Abemaciclib can slow the growth of cancer cells.\n\n### Uses:\n- **Breast Cancer:** Specifically, Abemaciclib is used to treat hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. It's used in combination with endocrine therapy (aromatase inhibitors) or as a monotherapy in patients who have previously undergone endocrine therapy but seen their cancer progress.\n  \n### Mechanism of Action:\nAbemaciclib targets and blocks CDK4 and CDK6 proteins, leading to the prevention of cell cycle progression from G1 to S phase,"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 36, "completion_tokens": 200, "total_tokens": 236}, "system_fingerprint": "fp_729ea513f7"}}, "error": null}
{"id": "batch_req_wDf6rbjPTMK3gcgTLmXL2Kke", "custom_id": "2_sentiment_question_about_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "bec907628cb4e054cf11fc94d412c506", "body": {"id": "chatcmpl-9RR1WjmYxZbxzixbvbKk1d2RwKTvE", "object": "chat.completion", "created": 1716325762, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Abiraterone is a medication primarily used in the treatment of prostate cancer. It works by inhibiting the production of androgens (male hormones) which can stimulate the growth of cancer cells in the prostate.\n\nHere are some key points about Abiraterone:\n\n1. **Mechanism of Action**: Abiraterone acetate is a prodrug, which means it is converted in the body to its active form, abiraterone. It inhibits an enzyme called CYP17A1, which is involved in the production of androgens in the adrenal glands, testes, and prostate tumor tissue. By blocking this enzyme, Abiraterone reduces the levels of androgens, which can slow the growth of prostate cancer cells.\n\n2. **Indications**: It is primarily used to treat metastatic castration-resistant prostate cancer (mCRPC) as well as high-risk metastatic hormone-sensitive prostate cancer (mHSPC).\n\n3. **Administration**: Abiraterone"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 36, "completion_tokens": 200, "total_tokens": 236}, "system_fingerprint": "fp_729ea513f7"}}, "error": null}
{"id": "batch_req_yDsJlLVxUbrRk9azlxiZrYTV", "custom_id": "3_sentiment_question_about_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "4e189aba6ff0d7f1fcea5b5a45b25684", "body": {"id": "chatcmpl-9RR1XoDUr6M5Dbp73GUKWB2BPxr2n", "object": "chat.completion", "created": 1716325763, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Acalabrutinib, marketed under the brand name Calquence, is a medication used in the treatment of certain types of blood cancers. It is primarily used to treat mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). \n\nAcalabrutinib operates as a Bruton's tyrosine kinase (BTK) inhibitor. BTK plays a critical role in B-cell receptor signaling, which is crucial for the growth and survival of malignant B cells. By inhibiting BTK, acalabrutinib helps prevent the proliferation of these cancerous cells.\n\nSome of the common side effects of acalabrutinib include headache, diarrhea, muscle pain, and upper respiratory tract infections. More serious potential side effects may include bleeding problems, infections, and a decrease in blood cell counts.\n\nIt is taken orally in capsule form, and the dosage is typically determined by a healthcare provider based on the individual's specific condition and treatment plan"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 37, "completion_tokens": 200, "total_tokens": 237}, "system_fingerprint": "fp_927397958d"}}, "error": null}
{"id": "batch_req_EDx5BaDVyhi9Nrnc7Ng7ACSC", "custom_id": "4_sentiment_question_about_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "9470e2f9451b7124c6735f8ed2c14321", "body": {"id": "chatcmpl-9RR1WzEXDdRlFEjxcvCdyE4PBdSDz", "object": "chat.completion", "created": 1716325762, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Aclarubicin is an anthracycline antibiotic used as a chemotherapeutic agent primarily in the treatment of various types of cancer, including leukemia and lymphomas. Like other anthracyclines, it works by intercalating DNA, thereby disrupting the function of the enzyme topoisomerase II, which is essential for DNA replication and cell division. This disruption ultimately leads to cell death, particularly in rapidly dividing cancer cells.\n\nHere are some key points about aclarubicin:\n\n1. **Mechanism of Action**: Aclarubicin intercalates into DNA, inhibiting topoisomerase II and causing breaks in the DNA strands. This action prevents the replication of DNA and the transcription of RNA, leading to apoptosis (programmed cell death) in cancerous cells.\n\n2. **Usage**: It is primarily used in the treatment of hematological malignancies, such as acute myeloid leukemia. It can be administered alone or in combination with other chemotherapy drugs.\n\n3"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 36, "completion_tokens": 200, "total_tokens": 236}, "system_fingerprint": "fp_729ea513f7"}}, "error": null}
{"id": "batch_req_ywbnMXyL8rgz9XdzFwh1VVRG", "custom_id": "5_sentiment_question_about_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "64a92a1eb28a33eb41c881fcd1889238", "body": {"id": "chatcmpl-9RR1WnEgArk2D6WSldCvYb6t4j20x", "object": "chat.completion", "created": 1716325762, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Certainly! Trastuzumab emtansine, also known by the brand name Kadcyla, is a targeted cancer therapy used primarily to treat certain types of breast cancer. It is an antibody-drug conjugate that combines the monoclonal antibody trastuzumab (Herceptin) with a chemotherapy drug called DM1 (a derivative of maytansine).\n\nHere is a more detailed breakdown of how it works:\n\n1. **Trastuzumab Component**:\n   - **Mechanism**: Trastuzumab is a monoclonal antibody that specifically targets the HER2 receptor, a protein that can promote the growth of cancer cells. This receptor is overexpressed in some breast cancers, referred to as HER2-positive cancers.\n   - **Action**: By binding to the HER2 receptor on the surface of cancer cells, trastuzumab can inhibit cell growth and signal the immune system to destroy the cancer cells.\n\n2. **DM1 Component**:\n   - **"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_927397958d"}}, "error": null}
{"id": "batch_req_as1FYt04e5YCEK15lRisumFq", "custom_id": "6_sentiment_question_about_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "4bd2e440fbe444f146ba91b0e136dd16", "body": {"id": "chatcmpl-9RR1XKGhuj81DsrXNGar58M5Wgc16", "object": "chat.completion", "created": 1716325763, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Afatinib is an anti-cancer medication that belongs to a class of drugs known as tyrosine kinase inhibitors (TKIs). It is primarily used to treat non-small cell lung cancer (NSCLC). Here's some detailed information about Afatinib:\n\n### Mechanism of Action\nAfatinib works by blocking certain proteins called epidermal growth factor receptors (EGFR) and human epidermal growth factor receptor 2 (HER2). These proteins are involved in the growth and spread of cancer cells. By inhibiting these receptors, Afatinib can help to slow down or stop the proliferation of cancer cells.\n\n### Indications\nAfatinib is typically prescribed for:\n- First-line treatment of NSCLC with specific mutations in the EGFR gene.\n- Treatment of NSCLC that has spread to other parts of the body (metastatic NSCLC).\n\n### Administration\nAfatinib is usually taken as an oral tablet once daily. It is important to follow the specific dosing instructions provided by a"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 35, "completion_tokens": 200, "total_tokens": 235}, "system_fingerprint": "fp_927397958d"}}, "error": null}
{"id": "batch_req_7ZAMg9xpZY65572xqGNFViX5", "custom_id": "7_sentiment_question_about_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "b16a656a4181b75b0e697765b1befe3d", "body": {"id": "chatcmpl-9RR1Xshlastbe0tdZRtD877yvOrPm", "object": "chat.completion", "created": 1716325763, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Aldesleukin, also known by its brand name Proleukin, is a form of interleukin-2 (IL-2) that is used as a medication primarily in the treatment of certain cancers, including metastatic renal cell carcinoma (kidney cancer) and metastatic melanoma (skin cancer). It is a type of immunotherapy that works by stimulating the immune system to attack cancer cells.\n\nHere's how Aldesleukin functions:\n1. **Immunostimulation**: Aldesleukin activates lymphocytes, a type of white blood cell that plays a key role in the immune response. Specifically, it increases the proliferation and activity of cytotoxic T-cells and natural killer (NK) cells, which can target and destroy cancer cells.\n   \n2. **Cytokine Production**: It enhances the production of other cytokines, which are signaling proteins that help direct the immune response.\n\n### Administration\n- **Route**: Aldesleukin is typically administered intravenously.\n"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 36, "completion_tokens": 200, "total_tokens": 236}, "system_fingerprint": "fp_729ea513f7"}}, "error": null}
{"id": "batch_req_GwGhYhdSVcdiLy3EDKEq18r1", "custom_id": "8_sentiment_question_about_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "a79577d391950e4564bcd7c7bc7f9ef7", "body": {"id": "chatcmpl-9RR0Zly24VUpjsEwxRqW6yOThLbVt", "object": "chat.completion", "created": 1716325703, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Alectinib is a medication primarily used to treat a specific type of non-small cell lung cancer (NSCLC). It belongs to a class of drugs known as tyrosine kinase inhibitors and specifically targets anaplastic lymphoma kinase (ALK). Here are some key points about Alectinib:\n\n1. **Indication**: Alectinib is indicated for patients with ALK-positive metastatic non-small cell lung cancer (NSCLC). ALK-positive means that the cancer cells have a mutation in the ALK gene which promotes the growth of the cancer.\n\n2. **Mechanism of Action**: Alectinib works by inhibiting the activity of the ALK protein, which is involved in the proliferation and survival of cancer cells. By blocking ALK, Alectinib can help slow or stop the growth of the cancer.\n\n3. **Administration**: Alectinib is administered orally in the form of capsules. The dosage and treatment schedule are determined by a healthcare provider"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 36, "completion_tokens": 200, "total_tokens": 236}, "system_fingerprint": "fp_927397958d"}}, "error": null}
{"id": "batch_req_WG9CiX1kQMb0mNm5eD2lMhYs", "custom_id": "9_sentiment_question_about_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "24786961196b22669c3877942d69854f", "body": {"id": "chatcmpl-9RR0Zt7mL0n7dEDPuInaLx2Gihqhv", "object": "chat.completion", "created": 1716325703, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Alemtuzumab is a monoclonal antibody medication primarily used to treat certain types of cancer and autoimmune diseases. It specifically targets CD52, a protein found on the surface of mature lymphocytes, which are a type of white blood cell involved in the body's immune response. By binding to CD52, alemtuzumab helps destroy these lymphocytes, thereby modulating the immune system.\n\n### Uses\n1. **Multiple Sclerosis (MS):** Alemtuzumab is generally prescribed for relapsing-remitting multiple sclerosis (RRMS) in patients who have not responded adequately to at least two other medications.\n2. **Chronic Lymphocytic Leukemia (CLL):** It can also be used for treating B-cell chronic lymphocytic leukemia, particularly in cases where the disease has progressed despite other treatments.\n\n### Mechanism of Action\nAlemtuzumab works by binding to the CD52 antigen on the surface of lymphocytes. This binding mobilizes the body's immune system"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 36, "completion_tokens": 200, "total_tokens": 236}, "system_fingerprint": "fp_729ea513f7"}}, "error": null}
{"id": "batch_req_dnQ6vlA9pmteXWD2LwDf3eQk", "custom_id": "10_sentiment_question_about_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "2c6aa9daf5fd8f13a88184ac29fd213f", "body": {"id": "chatcmpl-9RR0ZzcspwW8PQtvqaqv6z8gxZJWB", "object": "chat.completion", "created": 1716325703, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "All-trans retinoic acid (ATRA) is a derivative of vitamin A that plays a critical role in the regulation of gene expression, cell differentiation, and cell proliferation. It is the acidic form of vitamin A and functions as a ligand for nuclear receptors, specifically the retinoic acid receptors (RARs) and retinoid X receptors (RXRs). These receptors act as transcription factors that regulate the expression of various genes involved in cellular growth, differentiation, and apoptosis.\n\nClinically, ATRA is most well-known for its use in the treatment of acute promyelocytic leukemia (APL), a subtype of acute myeloid leukemia. In APL, a chromosomal translocation leads to the formation of a fusion protein that disrupts normal cell differentiation. ATRA helps to overcome this block, promoting the maturation and differentiation of immature blood cells into fully functioning cells. This differentiation therapy, often combined with other treatments like chemotherapy or arsenic trioxide, has significantly improved outcomes in APL"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 38, "completion_tokens": 200, "total_tokens": 238}, "system_fingerprint": "fp_729ea513f7"}}, "error": null}
